拜登籲地方政府每人派100美元吸引民衆接種疫苗
美國總統拜登呼籲州及地方政府以向民衆派發每人100美元,作爲吸引民衆接種新冠疫苗的誘因。
拜登引述加州大學研究指,洛杉磯約三分之一未接種疫苗人士聲稱派錢能鼓動他們去接種。他指早前通過的新一輪紓困措施,允許地方政府動用資源鼓勵民接種。他將逐一向地方政府遊說,動用有關資金提供每人100美元誘因,令民衆接種疫苗。
紐約州州長白思豪早前宣佈,將向在政府接種點接種首劑疫苗人士每人派發100美元。
美國疾控中心數據顯示,美國上週日(25日)有近80萬人接種新冠疫苗,截至昨日(29日)七天日均接種61.5萬劑,但遠低於4月中的單日逾300萬人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.